Penny Stocks to Watch as Artificial Intelligence Sweeps the Healthcare Sector: AHI, POAI, LTRN, SOUN

Generative artificial intelligence is the latest sensation taking over the investment world. Talk that the technology could generate up to $90 trillion in enterprise value by 2030, according to Ark Investment Management Big Ideas, explains the increased focus and attention on AI-focused plays.

AI penny stocks will always stand out as they offer a high-risk, high, upside exposure to companies focused on revolutionary technological innovations.  Given that most of the company’s trade for pennies and operate in niche markets, they offer an opportunity to gain more down the line.

As AI becomes the next big thing influencing all aspects of human lives, long-term investors may want to focus on the following:

Advanced Health Intelligence: A Full-Suite Biometric Health Risk Assessment Company

Advanced Health Intelligence (NASDAQ:AHI) is one company on the cusp of something big as artificial intelligence company moves to reshape the way diseases are diagnosed and treated and how patients are monitored. It has transformed from a company focused on capturing body dimensions using its smartphone proprietary BodyScan technology to a full-suite biometric health risk assessment company.

Consequently, Advanced Health Intelligence now appeals to a broader audience across healthcare, insurance, population health and non-government organizations. Its ability to deliver stable health assessment risk stratification and digital triage to healthcare providers positions it for tremendous growth even as AI brings groundbreaking changes to the healthcare sector.

Following the acquisition of Wellteq Digital Health Group and Vertica Health and the integration of all the acquired platforms, the company is now in a position to enable cost-effective health accessibility for smartphone users. It can also empower people to take full control of their health outcomes.

Therefore, it does not come as a surprise that the company’s solutions are eliciting strong demand for healthcare providers to insurers, employers and government agencies. The strong demand can only affirm solid long-term prospects and growth metrics.

After achieving its highest quarterly revenue of $253,355   in its first full quarter of operation, Advanced Health Intelligence can register further increases. The company is poised to benefit from a series of strategic partnerships with Bupa Health Insurance, whereby it delivers a white-label corporate team challenge application to wellness customers. AHI is to continue supporting existing solutions to Bupa with its partnership generating $900,000 in the first 12 months.

It also boasts of a strategic partnership with Nib Health Insurance whereby it supports its Payer to Partner strategy. The annual recurring revenue from the contract is AUD$687,676. Advanced Health Intelligence also boasts of a strategic partnership with Uviol Healthnet, which offers comprehensive medical, health and wellness practitioners’ technology and Augmented Reality Concierge, which empowers companies and people to simplify and enhance their surroundings.

That said, Advanced Health Intelligence looks highly undervalued following its transition into a company that offers a full suite of biometric health risk assessments. Its solutions eliciting strong demand from healthcare insurance and other health-focused organizations affirm its long-term prospects. With revenues expected to increase significantly, its valuation is also expected to improve, making it perfect for riding the AI revolution in the healthcare sector.

Predictive Oncology AI Drug Development Edge

Predictive Oncology (NASDAQ:POAI) is another penny stock in the healthcare sector that has been on the move as the market takes note of its proprietary machine learning and artificial intelligence capabilities. The company is leveraging advanced technologies to enhance oncologic drug discovery and enable drug development.

The company is fresh from delivering strong Q1 results supported by three significant contracts with Integra Therapeutics, Cvergenx, and Cancer Research Horizons. The three are expected to utilize the company’s PEDAL platform to expedite early drug discovery.

As a distinguished leader in artificial Intelligence-assisted drug discovery, Predictive Oncology has made important strides in tapping into opportunities in the multibillion-dollar industry. The efforts will not only benefit patients but also create long-term shareholder value.

Lantern Pharma Inc: Enhancing AI Drug Development Process

Lantern Pharma Inc. (NASDAQ:LTRN) is another highly prospective company on its way to becoming a big player in the fight against cancer using artificial intelligence technology. The company is already leveraging machine learning AI and advanced genomics to enhance the treatment of various cancer treatments.

Its proprietary AI platform RADR scans over 25 billion data points crucial to identifying beneficial compounds for cancer patients. Likewise, the platform could be a game changer in enhancing current cancer-related treatments as the company also enhance drug delivery costs and timelines using AI

While traditional early-stage drug discovery normally takes 3 to 5 years, its proprietary platform could reduce it to 2 years. The costs of coming up with new drugs are also expected to reduce by more than 70% using the new AI-powered model.

SoundHound AI Fueling AI Powered Voice Assistants

Valued at about $652 million, SoundHound AI Inc. (NASDAQ:SOUN) is a company that could enjoy tremendous growth and success in 70% of companies adopting AI. The company is already making a name for itself in developing a voice artificial intelligence platform that allows businesses to deliver high-quality conversation experiences to customers.

Its Houndify platform allows brands to build conversational assistants to interact with customers freely. The fact that automotive giants like Mercedes-Benz, Hyundai and Honda are already using AI voice assistants in their cars underscores their effectiveness and strong demand. The company also services the entertainment industry, with its biggest customer being Netflix, restaurants, and hospitality businesses.

Therefore, SoundHound is a perfect play for any investor looking to gain exposure to the use of AI to power voice assistants in various sectors.